Results

1–10 of 18 results for Neovascular Age‐related Macular Degeneration

Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
AI-Based Spatiotemporal Observations of Retinal Fluid Dynamics Using the Notal Vision Home OCT
Anat Loewenstein, MD
Annual Meeting Talks
2022
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021
Treatment Patterns and Visual and Health Function in Neovascular Age-Related Macular Degeneration (nAMD): Medicare Current Beneficiary Survey Analysis
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2021
Long-term Experience With Intravitreal Anti-VEGF Treatment in Patients With nAMD: Analysis of IRIS® (Intelligent Research in Sight) Registry Database
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2021